In the Claims

Claims 1-28 (Cancelled)

Claim 29 (Currently amended): A method for inducing proliferation of human embryonic stem cells or human hematopoietic stem cells that express SIP-110, comprising introducing anti-SIP-110 shRNA into the stem cells, wherein the shRNA reduces SIP-110 expression in the stem cells.

Claims 30-31 (Cancelled)

Claim 32 (Previously presented): The method of claim 31, wherein the shRNA is introduced into the stem cells by electroporation.

Claims 33-34 (Cancelled)

Claim 35 (Previously presented): The method of claim 32, wherein the SIP-110 comprises the nucleotide sequence of SEQ ID NO:3.

Claims 36-38 (Cancelled)

Claim 39 (Previously presented): The method of claim 29, wherein the stem cells are embryonic stem cells.

Claim 40 (Previously presented): The method of claim 29, wherein the stem cells are hematopoietic stem cells.

Claims 41-42 (Cancelled)

Claim 43 (Currently amended): A method for inducing proliferation of mouse embryonic stem cells or mouse hematopoietic stem cells that express s-SHIP, comprising introducing anti-s-SHIP shRNA into the stem cells, wherein the shRNA reduces s-SHIP expression in the stem cells.

Claim 44 (Previously presented): The method of claim 43, wherein the shRNA is introduced into the stem cells by electroporation.

Claim 45 (Previously presented): The method of claim 43, wherein the s-SHIP comprises the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:2.

Claim 46 (Previously presented): The method of claim 43, wherein the stem cells are embryonic stem cells.

Claim 47 (Previously presented): The method of claim 43, wherein the stem cells are hematopoietic stem cells.

Claims 48-49 (Cancelled)

Claim 50 (Previously presented): A method for inducing proliferation of human hematopoietic stem cells or human embryonic stem cells, comprising introducing anti-SHIP-110 shRNA into the hematopoietic or embryonic stem cells *in vitro*, wherein the shRNA reduces SIP-110 expression in the stem cells.

Claim 51 (Previously presented): A method for inducing proliferation of mouse hematopoietic stem cells or mouse embryonic stem cells that express s-SHIP, comprising introducing anti-s-SHIP shRNA into the hematopoietic stem cells or embryonic cells *in vitro*, wherein the shRNA reduces s-SHIP expression in the stem cells.